Corvus Pharmaceuticals, Inc. short interest in 2020
In 2020, Corvus Pharmaceuticals, Inc.'s disclosed short interest ran from 4.59% of shares outstanding on 15 Jan 2020 to 4.27% on 31 Dec 2020, a change of -0.32 percentage points. The year's high was 5.77% on 31 Jul 2020 and its low 4.06% on 15 May 2020, averaging 4.78% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.65 days on 30 Apr 2020. Full history: Corvus Pharmaceuticals, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2020 in figures
- Start of year
- 4.59% (15 Jan 2020)
- End of year
- 4.27% (31 Dec 2020)
- Change
- -0.32 pp
- High
- 5.77% (31 Jul 2020)
- Low
- 4.06% (15 May 2020)
- Average
- 4.78%
- Highest days to cover
- 19.65 (30 Apr 2020)
- SEC filings marked
- 8
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 4.59% | 10.48 | |
| 31 Jan 2020 | 4.33% | 8.21 | |
| 14 Feb 2020 | 4.53% | 6.12 | |
| 28 Feb 2020 | 4.34% | 8.13 | |
| 13 Mar 2020 | 4.26% | 5.85 | results (8-K), 10-K filed |
| 31 Mar 2020 | 4.31% | 11.97 | |
| 15 Apr 2020 | 4.31% | 13.94 | |
| 30 Apr 2020 | 4.24% | 19.65 | 10-Q filed, results (8-K) |
| 15 May 2020 | 4.06% | 5.33 | |
| 15 Jul 2020 | 4.41% | 1.00 | |
| 31 Jul 2020 | 5.77% | 2.59 | 10-Q filed, results (8-K) |
| 14 Aug 2020 | 5.65% | 5.85 | |
| 31 Aug 2020 | 5.77% | 10.15 | |
| 15 Sep 2020 | 5.71% | 5.39 | |
| 30 Sep 2020 | 4.89% | 8.25 | |
| 15 Oct 2020 | 5.32% | 1.00 | |
| 30 Oct 2020 | 5.44% | 10.21 | 10-Q filed, results (8-K) |
| 13 Nov 2020 | 4.94% | 10.12 | |
| 30 Nov 2020 | 4.92% | 11.26 | |
| 15 Dec 2020 | 4.40% | 6.46 | |
| 31 Dec 2020 | 4.27% | 7.47 |
See also: Corvus Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.